|Bid||59.59 x 1000|
|Ask||60.20 x 800|
|Day's range||58.59 - 61.51|
|52-week range||34.88 - 277.80|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||150.60|
Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.
Novavax (NVAX) closed the most recent trading day at $61.93, moving +1.34% from the previous trading session.